Primary_lymphoid and hematopoietic malignant neoplasms (controls excluding all cancers)

CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector

Check conditions None

diagram downward connector

Check pre-conditions, main-only, mode, registry filters None

0 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

7519

diagram downward connector
CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC_EXALLC

Control definitions

Control exclude C3_CANCER

Extra metadata

Level in the ICD hierarchy 2
First used in FinnGen datafreeze DF2

Similar endpoints

List of similar endpoints to Primary_lymphoid and hematopoietic malignant neoplasms (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 7519 3213 4306
Unadjusted prevalence (%) 1.99 1.52 2.59
Mean age at first event (years) 60.99 58.32 62.98

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.09 6.19 [4.62, 8.30] 2.7e-34 1833
15 years 0.01 2.10 [1.62, 2.73] 3.1e-8 478
5 years 0.01 6.08 [5.07, 7.30] 2.6e-83 587
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC_EXALLC – Primary_lymphoid and hematopoietic malignant neoplasms (controls excluding all cancers)
GWS hits: 8

Survival analyses between endpoints

Plot

before Primary_lymphoid and hematopoietic malignant neoplasms (controls excluding all cancers)
after Primary_lymphoid and hematopoietic malignant neoplasms (controls excluding all cancers)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Primary_lymphoid and hematopoietic malignant neoplasms (controls excluding all cancers)

Endpoint not on priority list, no data to show.